Comparative Pharmacology
Head-to-head clinical analysis: AMOXICILLIN PEDIATRIC versus BICILLIN L A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMOXICILLIN PEDIATRIC versus BICILLIN L A.
AMOXICILLIN PEDIATRIC vs BICILLIN L-A
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin is a semisynthetic penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). It blocks the transpeptidation step in peptidoglycan cross-linking, leading to cell lysis and death.
Penicillin G benzathine is a slow-release formulation that provides prolonged tissue concentrations. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes, leading to cell lysis.
250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours for adults.
1.2 million units intramuscularly as a single dose for treatment of streptococcal pharyngitis; for syphilis, 2.4 million units intramuscularly weekly for 1-3 weeks depending on stage.
None Documented
None Documented
Terminal elimination half-life: 1-1.5 hours in children with normal renal function; prolonged to 7-21 hours in anuria.
Terminal half-life: 30-60 hours (prolonged due to slow absorption from IM depot; clinically allows single-dose regimen for syphilis)
Renal: 60-80% unchanged via glomerular filtration and tubular secretion; biliary: minor (<10%); fecal: <5%.
Renal: 60-90% unchanged; biliary/fecal: minor (<10%)
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic